Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Erlotinib

  • Bassel El-Rayes
  • Shirish Gadgeel
  • Shadan Ali
  • Philip A. Philip
  • Fazlul H. Sarkar
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1989-3

Synonyms

Definition

Erlotinib is a potent and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Erlotinib is commercially available in tablets of 25, 100, and 150 mg formulations. Erlotinib is currently approved for use in previously treated non-small cell lung cancer and in frontline management of pancreatic cancer in combination with gemcitabine chemotherapy.

Characteristics

Rationale for Targeting the EGFR. The EGFR is frequently dysregulated in epithelial cancers. Overexpression of EGFR can result in malignant transformation of cells. Patients whose tumors have overexpressed or dysregulated EGFR and/or ligand expression may have a worse prognosis. Activation of the EGFR initiates dimerization of the receptors leading to activation of the tyrosine kinase domain. The kinase in turn phosphorylates (Phosphorylation) and activates proteins in the signal transduction cascade promoting cell proliferation, angiogenesis, invasion, and survival. In...

Keywords

Epidermal Growth Factor Receptor Pancreatic Cancer Epidermal Growth Factor Receptor Mutation Advanced NSCLC Advanced Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. El-Rayes BF, LoRusso PM (2004) Targeting the epidermal growth factor receptor. Br J Cancer 91:418–424CrossRefPubMedPubMedCentralGoogle Scholar
  2. Giaccone G (2005) Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncol 1:449–460CrossRefPubMedGoogle Scholar
  3. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369–385CrossRefPubMedGoogle Scholar
  4. Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663CrossRefPubMedGoogle Scholar
  5. Philip PA, Mahoney MR, Allmer C et al (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069–3074CrossRefPubMedGoogle Scholar

See Also

  1. (2012) Bile Duct. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 399. doi:10.1007/978-3-642-16483-5_616Google Scholar
  2. (2012) Capecitabine. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 640. doi:10.1007/978-3-642-16483-5_828Google Scholar
  3. (2012) FOLFIRI. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1440. doi:10.1007/978-3-642-16483-5_2232Google Scholar
  4. (2012) FOLFOX. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 1441. doi:10.1007/978-3-642-16483-5_2233Google Scholar
  5. (2012) Phosphorylation. In: Schwab M (ed) Encyclopedia of Cancer, 3rd edn. Springer Berlin Heidelberg, p 2870. doi:10.1007/978-3-642-16483-5_4544Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Bassel El-Rayes
    • 1
    • 2
  • Shirish Gadgeel
    • 3
  • Shadan Ali
    • 3
  • Philip A. Philip
    • 3
  • Fazlul H. Sarkar
    • 3
  1. 1.Department of Hematology and Medical OncologyEmory University School of MedicineAtlantaUSA
  2. 2.Winship Cancer Institute of Emory UniversityAtlantaUSA
  3. 3.Karmanos Cancer InstituteWayne State UniversityDetroitUSA